Ordin nr. 1301/500/2008 din 11 iulie 2008 Partea a ii-a

Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L03AB11 PEGINTERFERON alfa-2a SOL. INJ. 135 µg/ml

PEGASYS 135 µg/ml 135 µg/ml ROCHE REGISTRATION LTD.
L03AB11 PEGINTERFERON alfa-2a SOL. INJ. ÎN SERINGĂ 180 µg/0.5 ml

PREUMPLUTĂ

PEGASYS 180 µg/0,5 ml 180 µg/0.5 ml ROCHE REGISTRATION LTD.

________________________________________________________________________________

______________________________________________________________________________

| 422 |N04BB01| AMANTADINUM** | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

N04BB01 AMANTADINUM CAPS. 100 mg

VIREGYT(R)-K 100 mg EGIS PHARMACEUTICALS LTD.

________________________________________________________________________________

SUBLISTA C1 - G10 LEUCEMII, LIMFOAME, APLAZIE MEDULARĂ, GAMAPATII MONOCLONALE MALIGNE, MIELOPROLIFERĂRI CRONICE ŞI TUMORI MALIGNE, SINDROAME MIELODISPLAZICE.